Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SSG XX Protocol for High-Risk Soft Tissue Sarcoma
NCT00790244Phase 2Unknown
- Sponsor
- Oslo University Hospital
- Start
- Oct 2007
- Primary completion
- Oct 2012
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label trial of doxorubicin and ifosfamide in soft tissue sarcoma (STS) (4 arms), sponsored by Oslo University Hospital. Primary endpoint: Metastases-free survival at 5 years. Status: unknown.
02
Drugs
doxorubicinifosfamide
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT00790244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00790244.